Context

Hepatitis B (HBV) remains a global health concern with 350 million people chronically infected, and transmission still occurs despite the widely available and efficacious vaccine. Mother-to-child transmission (MTCT) is an ongoing problem in many countries, and in countries with high prevalence of HBV (>8%), only 44% have birth dose vaccine implemented into the infant vaccine schedule.1 Currently, the Centers for Disease Control and Prevention recommends the use of hepatitis B immune globulin (HBIG) and HBV vaccine given at the time of birth with two additional doses of the vaccine in the first 6 months of life to …